Second, we will intensify our support for innovation for public and animal health. We will further enhance our early development support to enable new medicines to be authorised in the EU as rapidly as possible.

Third, we will continue to invest in our staff and build the network of tomorrow. This investment in the European medicines regulatory network’s workforce will help build capacity and capability so that we can fully embrace the new challenges and opportunities that lie ahead.

At the end of the year, we can look with pride at its achievements. In 2025, we recommended 104 new medicines for human use. Almost 40% of them contain a completely new active substance. In the veterinary area, we recommended a record-breaking 30 new medicines, among them several new vaccines. There were many remarkable new treatments, both in human and veterinary medicine, and let me highlight just a few:

• the first treatment to delay the onset of stage 3 type 1 diabetes in adults and…